Moreover, the treatment with BCL2 inhibitors was shown to induce the activation of cDC1s detectable in circulation, both in mice and in patients, altogether underlining that BCL2 acts as a cDC1-specific immune checkpoint that restrains tumor immunosurveillance [60, 61]. Here, BCL2 is linked to neoplasm.